Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients

European Journal of Radiology

Volumn 80, Issue 3, 2011, Pages 655-661

  Desar, Ingrid M E ^a   Van Herpen, Carla M L ^a   Van Asten, Jack J A ^a   Fiedler, Walter ^b   Marreaud, Sandrine ^c   Timmer Bonte, Johanna N H ^a   Ter Voert, Edwin G W ^a   Lambiase, Antonio ^d   Bordignon, Claudio ^d   Heerschap, Arend ^a   Van Laarhoven, Hanneke W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c EORTC DATA CENTER   (Belgium)

^d MOLMED S P A   (Italy)

Author keywords

Biomarkers; Cancer; DCE MRI; NGR hTNF

Indexed keywords

HUMAN TUMOR NECROSIS FACTOR COUPLED TO PEPTIDE NGR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SIZE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; HISTOGRAM; HUMAN; KINETICS; LIVER; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REPRODUCIBILITY; SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

AGED; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMPUTER-ASSISTED; FEMALE; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASMS; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80755126659     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2010.08.045     Document Type: Article

References (22)

1. F. Curnis, A. Sacchi, and L. Borgna Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) Nat Biotechnol 18 11 2000 1185 1190
2. C. Ruegg, A. Yilmaz, and G. Bieler Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma Nat Med 4 4 1998 408 414 (Pubitemid 28212755)
3. B. Stoelcker, B. Ruhland, and T. Hehlgans Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature Am J Pathol 156 4 2000 1171 1176 (Pubitemid 30659994)
4. H.W. van Laarhoven, G. Gambarota, and A. Heerschap Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas Invest New Drugs 24 1 2006 27 36 (Pubitemid 43163422)
5. F. Curnis, A. Sacchi, and A. Corti Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration J Clin Invest 110 4 2002 475 482 (Pubitemid 34919701)
6. H.W. van Laarhoven, W. Fiedler, and I.M. Desar Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041) Clin Cancer Res 16 4 2010 1351 1423
7. D. Aderka, P. Sorkine, and S. Abu-Abid Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock J Clin Invest 101 3 1998 650 659 (Pubitemid 28084249)
8. C. Le Tourneau, J.J. Lee, and L.L. Siu Dose escalation methods in phase I cancer clinical trials J Natl Cancer Inst 101 10 2009 708 720
9. A. Sacchi, A. Gasparri, and C. Gallo-Stampino Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha Clin Cancer Res 12 1 2006 175 182 (Pubitemid 43166192)
10. J.P. O'Connor, A. Jackson, G.J. Parker, and G.C. Jayson DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents Br J Cancer 96 2 2007 189 195 (Pubitemid 46160619)
11. K. Hittmair, G. Gomiscek, and K. Langenberger Method for the quantitative assessment of contrast agent uptake in dynamic contrast-enhanced MRI Magn Reson Med 31 5 1994 567 571 (Pubitemid 24129954)
12. H.W. van Laarhoven, M. Rijpkema, and C.J. Punt Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases J Magn Reson Imaging 18 3 2003 315 320 (Pubitemid 37046512)
13. H.W. van Laarhoven, D.W. Klomp, and M. Rijpkema Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil NMR Biomed 20 2 2007 128 140 (Pubitemid 46470935)
14. U. Duvvuri, H. Poptani, and M. Feldman Quantitative T1rho magnetic resonance imaging of RIF-1 tumors in vivo: detection of early response to cyclophosphamide therapy Cancer Res 61 Nov 1 21 2001 7747 7753 (Pubitemid 33049360)
15. J.M. Bland, and D.G. Altman Statistical methods for assessing agreement between two methods of clinical measurement Lancet 1 8476 1986 307 310 (Pubitemid 16134762)
16. A.R. Padhani, and M.O. Leach Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging Abdom Imaging 30 3 2005 324 341 (Pubitemid 40898066)
17. M.O. Leach, K.M. Brindle, and J.L. Evelhoch The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations Br J Cancer 92 9 2005 1599 1610 (Pubitemid 40756468)
18. D. Klomp, H. van Laarhoven, T. Scheenen, Y. Kamm, and A. Heerschap Quantitative 19F MR spectroscopy at 3 T to detect heterogeneous capecitabine metabolism in human liver NMR Biomed 20 5 2007 485 492 (Pubitemid 47272368)
19. M. Schmidinger, C.C. Zielinski, and U.M. Vogl Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 26 10, 32 2008 5204 5212
20. A. Ravaud, and M. Sire Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer Ann Oncol 20 5 2009 966 967
21. V. Gregorc, A. Santoro, and E. Bennicelli Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours Br J Cancer 101 2 2009 219 224
22. M.S. Gee, W.N. Procopio, and S. Makonnen Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy Am J Pathol 162 1 2003 183 193 (Pubitemid 36042000)